Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a

NACompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Prostate CancerProstate Cancer, FamilialHereditary Prostate Cancer
Interventions
GENETIC

Genetic Risk Score: Number Format

Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.

GENETIC

Genetic Risk Score: Number + Pictograph

Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

BEHAVIORAL

Family History: Number Format

Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

BEHAVIORAL

Family History: Number + Pictograph

Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Van Andel Research Institute

OTHER

collaborator

Spectrum Health Medical Group

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Wake Forest University Health Sciences

OTHER

lead

Endeavor Health

OTHER